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Objectives
The main goal of the First European conference on drug supply indicators was to launch the 
work needed to establish a set of technically sound and sustainable indicators for monitoring 
drug markets, crime and supply reduction for Europe. The event brought together for the first 
time a wide range of European and international experts to assess the current state of the art 
in this domain and develop a realistic strategy for moving forward in an area of importance 
for European drug policies. The conference was a joint venture between the European 
Commission (EC) and the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) with the active involvement of Europol. It represented an important first step 
towards achieving the objectives stated in the EU Drugs Action Plan (2009–12) and supports 
both the conclusions of the Commission’s recent paper on the way forward to improve key 
supply indicators and the EMCDDA in its work to fulfil its ongoing mandate to provide an 
overview of the European drug phenomenon. 
The conference was organised around three main thematic areas: the drug market, the 
drug-crime nexus, and drug supply reduction. In practical terms, the conference provided 
an opportunity to assess the current state of the art in data availability and reporting tools; 
to identify structural and practical barriers to data collection and explore how they can be 
overcome; and to assess new approaches and potential monitoring options. In addition, 
the conference started a process geared towards achieving consensus on a roadmap for 
scaling up existing approaches and practices, and establishing the basis for a network 
of both operational and scientific experts that will guide the future conceptualisation and 
implementation of European drug supply indicators.
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7Key conclusions and the way forward
The conference was a unique event bringing together for the first time law enforcement 
officials, forensic scientists, academics, experts and data analysts from national and 
international institutions to discuss the way forward for monitoring drug supply in Europe. 
More than 120 invited participants — with different backgrounds, skills and perspectives —
worked together during the three days of proceedings. It is expected that this first conference 
marks the starting point in a process of productive collaboration over the coming years.
There was agreement among participants on the pressing need to improve the knowledge 
base on drug supply issues in order to better design and target measures to fight against 
drug production and trafficking. This will be useful for policy-makers, including law 
enforcement strategic planning advisers. An important conclusion from the conference was 
that a considerable amount of data on drug supply is already being collected in a systematic 
way across the EU, and that the way forward is to build on what already exists — paying 
special attention to the potential for standardisation, extension and improvement of the data 
collection system(s) that are already in place. In terms of guiding principles to developments 
in drug supply indicators, there was agreement that the information providers must benefit 
from the information collected, routine data collection should be restricted to what is 
necessary and feasible rather than what would be ideal, and that there is a clear need for 
targeted research to broaden the understanding of the topic.
There was consensus among participants on the need to develop our understanding of supply 
reduction efforts and interventions. This is a key drug policy area, which receives a large 
amount of public funding, yet there exists a huge gap in the existing knowledge base. It is 
hoped that future work in this area will provide a useful source of trend information, help 
ensure that actions are well-targeted and effective, and allow the assessment of unintended 
consequences.
The development of a sound conceptual framework to monitor illicit drug supply in Europe 
will be an important place to start. It was recognised that the entire drug supply chain 
will need to be taken into consideration, as well as the fact that different countries will be 
affected by their own strategic and geographical position (producer/transit/consumer) on 
the supply chains for different substances. Experience has shown that developing a complete, 
coherent and standardised European information system based on key indicators will take 
time. It involves several steps, such as: needs assessment, conceptualisation, review of 
existing approaches, building of consensus, development and testing of standard instruments, 
development of implementation guidelines and, very importantly, the provision of some 
training to implement agreed standards. Working towards this would include the identification 
of key concepts, definition of information needs and priorities and the development of a new 
research agenda. This would be operationalised via a monitoring strategy and key indicators 
— which should be of a composite nature, building on and integrating existing monitoring 
approaches. The indicators will also need to be dynamic, allowing for the necessary 
adjustment to a constantly evolving drug supply phenomenon.
Both research and monitoring have important roles to play in terms of methodological 
approaches to our understanding of drug supply issues. The indicators will need to have 
both qualitative and quantitative components; complex models can help develop our 
understanding; and multi-indicator analysis will be essential. Particularly when focusing on 
drug markets, there will be a need to explore the integration of both supply and demand 
information.
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There was general agreement, however, that there are insufficient data available regarding 
the characteristics and the functioning of the illicit drug market (supply side). Reasons for 
this situation include: the scarcity of information sources, the fact that law enforcement data 
are sometimes ‘trapped’ within agencies; issues of data sensitivity and confidentiality; and 
operational priorities may influence both what it is possible to collect and the data available. 
A further constraint relates to data comparability, where individual Member State legislation, 
criminal justice practices and political priorities all have an impact. It is essential that these 
challenges are fully acknowledged and appropriately addressed in each phase of indicator 
development.
There was consensus among the participants that the overall conceptual framework to monitor 
illicit drug supply in Europe should integrate three components: drug markets, drug-related 
crime and drug supply reduction. It was recognised that there are strong links and overlaps 
between these areas, but for practical efficiency it appears suitable to organise the work in 
this way. The conference discussions stressed that in each of these areas there is first and 
foremost a need to identify current good practice and build upon what already exists by 
scaling up, rationalising and standardising current approaches. There is also a need to go 
beyond this and complement it by developing innovative approaches, reviewing analytical 
needs, and establishing research priorities. The final objective is to bring all this together 
in a practically grounded roadmap with clear short, medium and long term objectives for 
monitoring in each of the three areas of markets, crime and supply reduction.
Data sets on drug purity, drug tablet contents and drug prices are essential to the 
understanding of drug markets. They need to be audited and reporting practices reviewed 
across Europe. It is now time to achieve a consensus on core data and methodological 
approaches in this area by developing a European standard instrument tailored to different 
levels of the market (from retail to wholesale and importation). The instrument should 
include guidelines on data recording and reporting as well as identify analytical issues and 
approaches. These activities will allow implementation issues, barriers and opportunities to be 
identified.
Discussions among the participants highlighted in addition a number of avenues to explore 
for improving our knowledge base of illicit drug markets in Europe. Forensic science was in 
particular recognised as an essential area to exploit further for the monitoring of issues such 
as adulterants and mixtures of psychoactive substances, but also as a reporting framework 
linked to early warning systems on drugs across Europe, and to explore for its capacity 
to develop a European centralised system for the synthesis of reference material and the 
collection and analysis of drug samples. Other areas for development include: production 
and trafficking in drug precursors and essential chemicals; demand-side approaches for 
sizing the market; methods for generating purity-adjusted price data; the potential utility 
of wastewater analysis; Internet as a monitoring tool; and understanding illicit drugs as 
competing commodities (e.g. different stimulants). Launching a trans-national study on drug 
trafficking in Europe was also suggested.
There was a consensus among the participants that drug-related crime is a large and 
complex issue: it may refer to a variety of criminal acts that are difficult to link together in 
a commonly agreed framework. A definition of the term drug-related crime will provide a 
conceptual framework for identifying the areas where measurement is possible, but it needs 
to be practical and realistic. It also needs to be linked to other criminal justice data sets and 
routine police reporting. It was suggested to broaden the definition to look at actors and 
positions of the different crimes in the drug supply chain.
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Priorities for monitoring and research need to be established in the area of drugs and 
crime. Links between drug supply and organised crime and criminal hubs in Europe will 
need to be addressed. Intra-European production of illicit drugs is a major monitoring area 
where knowledge development is essential. Understanding the economic issues associated 
with the illicit drug trade is also a concern in Europe. Offences against drug legislation 
were acknowledged as an important component of drug supply monitoring, though it was 
also recognised that they are a direct indicator of law enforcement activity and priorities. 
The participants stressed the importance of reconciling the different data sets on drug law 
offences that are produced in Europe, and of agreeing on a common case definition. This 
will be a first step towards developing a European standard instrument, including guidelines 
for data collection and reporting. There are also areas that will likely be best addressed by 
research rather than through monitoring, for example the links between violence and drug 
supply activities, or the part of volume crime that may be attributed to illicit drugs.
Drug supply reduction is a broad, diverse and complex field where policing and criminal 
justice agencies play a central role. Drug policing is a multi-faceted activity involving a range 
of organisations, actors, methods and practices. However, care should be taken not to restrict 
supply reduction to drug law enforcement, and vice-versa. A clear conceptual framework 
of supply reduction is lacking, which hampers the overall understanding and consequently 
monitoring and evaluation of the area.
Drug supply reduction is also a wide and under-researched field. It is therefore essential to 
develop a set of priorities, at EU level, as to which sectors should be addressed first. There 
was consensus among the participants on initiating our work in this area by a mapping 
exercise with a view to producing a picture of drug supply reduction activities in Europe.  
The existence, role and practices of specialised drug units could be a starting point.  
Intra-European cooperation, how it is practically implemented and its benefits are another 
interesting issue. Some aspects in the field of alternative development may also be relevant 
for Europe. Discussions stressed that supply reduction activities are part of a bigger context 
in which global trends and developments need to be closely analysed for interpretation 
purposes.
Monitoring the supply of illicit drugs in Europe is a relatively new area and the constraints 
are numerous. Our ambitions need to be grounded in what is achievable. It is essential to 
differentiate between the information we ‘need to know’ and that it would be ‘nice to know’. 
It is important to recognise that many things in this field are not best done — or simply 
cannot be done — at the European level. We will also need to be realistic, as data collection 
may not necessarily be seen as an essential task by operational staff who are already 
overburdened. The way forward is not to set up a single system, but to develop synergies, 
strengthen the links between existing data providers, and recognise different perspectives. 
A critical issue is that information collection has to be seen as valuable and important by 
those providing the information. This implies that the system should have practical utility for 
those who contribute to it and this issue needs to be taken into account when considering the 
outputs from any data collection exercise.
Charting the way forward, discussions have shown that a starting point will be to streamline 
existing routine data on drug supply, so that the comparability, reliability and completeness of 
these data sets are improved across Europe. Then, it will be necessary to assess the feasibility 
of obtaining data from new sources, and in some cases recognise the value of accessing 
information and knowledge which is ‘trapped’ within the current system, especially for trend 
identification. Strategies to set up more rapid information exchange mechanisms will be 
considered.
EMCDDA	strategy	and	work	programme	2010–12
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Where do we go next? 
Work in the area of developing drug supply indicators has been anticipated in planning by 
the European Commission, Council, EMCDDA and Europol. The conference conclusions were 
presented at the November Horizontal Drug Group (HDG) meeting. 
As noted in the EU Drugs Action Plan 2009–12, work on the following tasks will continue:  
to develop a definition of drug-related crime; to identify key indicators; and to establish a  
practical strategy to collect the necessary information to construct the indicators. Options will also 
be explored as to what extent available research funds can support developmental activities in 
this area, although it is recognised that funding options are limited.
In terms of concrete next steps, the work started at the conference will be taken forward in 2011 
through the formation of three technical working groups reflecting the thematic areas addressed 
at the conference (markets, crime and supply reduction). These groups will be supported by the 
EMCDDA, and formally included in the 2011 work plan. Each group will assess the current state 
of play and, based on the conclusions noted above, develop a proposal for the adoption of a key 
indicator. 
Each proposal will consist of three parts,
a) a concept paper, which will provide the conceptual framework for the proposed tool, and 
include a discussion of methodological issues; 
b) a proposal for a key indicator, detailing scope and reporting categories;
c) an implementation roadmap. 
The result of this work will then be taken to a second consensus building conference in 2012 
where the working groups’ efforts will be critically reviewed and harmonised. At this meeting,  
any issues of overlap and consistency will be addressed. The conclusions of the 2012 meeting 
would form the basis for a proposal by the Commission to be considered by the Council on the  
introduction of key indicators on drug supply as envisaged by the current EU Drugs Action Plan.
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